中新网天津3月14日电 (记者 孙玲玲 焦德芳 郝夏冉)天津大学生命科学学院吕春婉团队在结直肠癌免疫治疗研究方面取得重大进展，成功研发出一款新型治疗药物。该成果已于近期发表在国际权威期刊《纳米》上，标志着中国在结直肠癌治疗领域迈出了重要的一步。
结直肠癌是常见的恶性肿瘤之一，全球范围内发病率逐年上升。尽管目前的治疗手段包括手术、化疗和放疗等，但对于一些晚期患者，疗效有限。因此，寻找新的治疗方法和药物一直是医学界研究的热点。
吕春婉团队的新型药物通过纳米技术递送肿瘤特异性抗原，激活患者自身的免疫系统，从而达到治疗结直肠癌的目的。这项研究为结直肠癌患者提供了新的治疗选择，有望提高患者的生存率和生活质量。
英文标题：Tianjin University Researchers Make Breakthrough in Colorectal Cancer Immunotherapy
英文关键词：Colorectal Cancer, Immunotherapy, Novel Drug
英文新闻内容：
Tianjin, China, March 14 (ANI): Researchers from the School of Life Sciences at Tianjin University have made significant progress in the field of colorectal cancer immunotherapy. They have successfully developed a new treatment drug, which has been published in the international authoritative journal, Nano.
Colorectal cancer is a common type of malignant tumor, with an increasing incidence worldwide. Although current treatments such as surgery, chemotherapy, and radiotherapy are available, they are often ineffective for some advanced patients. Therefore, the search for new treatment methods and drugs has been a hot topic in the medical community.
The novel drug developed by Professor Lv Chunwen’s team utilizes nanotechnology to deliver tumor-specific antigens, thereby activating the patient’s own immune system to treat colorectal cancer. This research offers new treatment options for colorectal cancer patients and is expected to improve patient survival rates and quality of life.
【来源】http://www.chinanews.com/life/2024/03-14/10180297.shtml
Views: 2